# A Long-term Safety Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome

> **NCT04252586** · PHASE3 · TERMINATED · sponsor: **Jazz Pharmaceuticals** · enrollment: 21 (actual)

## Conditions studied

- Rett Syndrome
- RTT

## Interventions

- **DRUG:** GWP42003-P

## Key facts

- **NCT ID:** NCT04252586
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-02-28
- **Primary completion:** 2021-06-09
- **Final completion:** 2021-06-09
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** Study was terminated due to COVID-19 pandemic and recruitment challenges in the parent study (GWND18064 - NCT03848832).
- **Last updated:** 2022-08-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04252586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04252586, "A Long-term Safety Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04252586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*